Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · IEX Real-Time Price · USD
3.84
+0.01 (0.26%)
At close: Dec 29, 2023, 4:00 PM
3.77
-0.07 (-1.82%)
After-hours: Dec 29, 2023, 7:19 PM EST
Company Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease.
The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.
Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Acumen Pharmaceuticals, Inc.
| Country | United States |
| Founded | 1996 |
| IPO Date | Jul 1, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 39 |
| CEO | Daniel J. O'Connell M.B.A. |
Contact Details
Address: 427 Park St. Charlottesville, Virginia 22902 United States | |
| Phone | 925-368-8508 |
| Website | acumenpharm.com |
Stock Details
| Ticker Symbol | ABOS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001576885 |
| CUSIP Number | 00509G209 |
| ISIN Number | US00509G2093 |
| Employer ID | 36-4108129 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Daniel J. O'Connell M.B.A. | Chief Executive Officer, President and Director |
| Matt Zuga | Chief Financial Officer, Chief Business Officer and Corporate Secretary |
| Dr. Eric Siemers M.D. | Chief Medical Officer |
| Russell Barton M.S. | Chief Operating Officer |
| Derek M. Meisner Esq., J.D. | Chief Legal Officer |
| Robyn Moxon M.A. | Manager of Corporate and Clinical Communications |
| Julie Bockenstette | Executive Vice President and Head of Human Resources |
| Siew Tin Gan M.S. | Assistant Vice President and Head of Clinical Operations |
| Janice Hitchcock | Vice President and Head of Regulatory Affairs |
| Liean Schenck M.S. | Vice President and Head of CMC |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 4, 2023 | 8-K | Current Report |
| Nov 13, 2023 | 8-K | Current Report |
| Nov 13, 2023 | 10-Q | Quarterly Report |
| Nov 13, 2023 | 8-K | Current Report |
| Nov 9, 2023 | 8-K | Current Report |
| Aug 17, 2023 | 144 | Filing |
| Aug 8, 2023 | 10-Q | Quarterly Report |
| Aug 8, 2023 | 8-K | Current Report |
| Jul 25, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jul 20, 2023 | 424B5 | Filing |